These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 3946465)

  • 21. Inotropic therapy of the failing myocardium.
    Om A; Hess ML
    Clin Cardiol; 1993 Jan; 16(1):5-14. PubMed ID: 8416761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Therapy of dilated cardiomyopathy with digitalis, diuretics and vasodilators].
    Liebau G
    Herz; 1985 Jun; 10(3):138-42. PubMed ID: 2991095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relative contribution of inotropic and vasodilator effects to amrinone-induced hemodynamic improvement in congestive heart failure.
    Konstam MA; Cohen SR; Weiland DS; Martin TT; Das D; Isner JM; Salem DN
    Am J Cardiol; 1986 Feb; 57(4):242-8. PubMed ID: 3004184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calcium channel blockers in congestive heart failure: theoretic considerations and clinical experience.
    Colucci WS; Fifer MA; Lorell BH; Wynne J
    Am J Med; 1985 Feb; 78(2B):9-17. PubMed ID: 3976695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experience with calcium antagonist drugs in congestive heart failure.
    O'Rourke RA; Walsh RA
    Am J Cardiol; 1987 Jan; 59(3):64B-69B. PubMed ID: 3812267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of novel inotropic agents in the treatment of heart failure.
    LeJemtel TH; Keren G; Reis D; Sonnenblick EH
    J Cardiovasc Pharmacol; 1986; 8 Suppl 9():S47-54. PubMed ID: 2433542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The dobutamine-dopamine combination versus amrinone in congestive heart failure with a marked edematogenic sign complicated by functional kidney failure. A comparison between 2 different models of inotropic stimulation and diuresis potentiation].
    De Vecchis R; Pucciarelli G; Nocerino L; Cocozza M; Setaro A; Torre G; Imperatore F
    Minerva Cardioangiol; 1998 May; 46(5):163-74. PubMed ID: 9842199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vasodilators and inotropic agents in the treatment of congestive heart failure.
    Francis GS
    Semin Nephrol; 1994 Sep; 14(5):464-78. PubMed ID: 7997651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vasodilator and inotropic agents in treatment of chronic cardiac failure: clinical experience and response in exercise performance.
    Weber KT; Andrews V; Kinasewitz GT; Janicki JS; Fishman AP
    Am Heart J; 1981 Sep; 102(3 Pt 2):569-77. PubMed ID: 6115574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pathophysiologic aspects and modern treatment of congestive heart failure].
    Rutishauser W
    Schweiz Med Wochenschr; 1986 Nov; 116(46):1587-92. PubMed ID: 3024312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Chronic heart failure: effect and evaluation of therapy with positive inotropic substances].
    Thormann J; Kramer W; Dieterich HA
    Herz; 1990 Jun; 15(3):190-201. PubMed ID: 2198220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic options in the management of chronic heart failure. Is there a drug of first choice?
    Packer M
    Circulation; 1989 Jan; 79(1):198-204. PubMed ID: 2562938
    [No Abstract]   [Full Text] [Related]  

  • 33. Acute substantial benefit of inotropic therapy with amrinone on exercise hemodynamics and metabolism in severe congestive heart failure.
    Siskind SJ; Sonnenblick EH; Forman R; Scheuer J; LeJemtel TH
    Circulation; 1981 Nov; 64(5):966-73. PubMed ID: 7285310
    [No Abstract]   [Full Text] [Related]  

  • 34. [Clinical effect of China-made amrinone in the treatment of refractory congestive heart failure].
    Han YL; Zhu SJ; Lu YM
    Zhonghua Nei Ke Za Zhi; 1990 Jun; 29(6):324-7, 381. PubMed ID: 2269028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medical treatment of congestive heart failure: where are we now?
    Parmley WW
    Circulation; 1987 May; 75(5 Pt 2):IV4-10. PubMed ID: 3552301
    [No Abstract]   [Full Text] [Related]  

  • 36. When should we use nitrates in congestive heart failure?
    Vizzardi E; Bonadei I; Rovetta R; D'Aloia A; Quinzani F; Curnis A; Dei Cas L
    Cardiovasc Ther; 2013 Feb; 31(1):27-31. PubMed ID: 22953723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Principles of therapy for congestive heart failure.
    Opie LH
    Eur Heart J; 1983 Jan; 4 Suppl A():199-208. PubMed ID: 6301836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vasodilator therapy for congestive heart failure. Lessons from mortality trials.
    Groden DL
    Arch Intern Med; 1993 Feb; 153(4):445-54. PubMed ID: 8435024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [New knowledge on the subject of therapy in cardiac decompensation in the light of large trials].
    Camerini F; Perkan A; Sinagra G; Di Lenarda A; Pinamonti B; Zecchin M
    Ann Ital Med Int; 1994 Oct; 9 Suppl():68S-77S. PubMed ID: 7857761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral amrinone in refractory congestive heart failure.
    Wynne J; Malacoff RF; Benotti JR; Curfman GD; Grossman W; Holman BL; Smith TW; Braunwald E
    Am J Cardiol; 1980 Jun; 45(6):1245-9. PubMed ID: 7377123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.